Nuvectis Pharma, Inc. (NVCT)
NASDAQ: NVCT · Real-Time Price · USD
18.49
-1.56 (-7.78%)
Oct 26, 2026, 4:00 PM EDT - Market closed
Nuvectis Pharma Employees
Nuvectis Pharma had 16 employees as of June 30, 2026. The number of employees increased by 3 or 23.08% compared to the same quarter last year. That makes Nuvectis Pharma the 38,987th largest employer in the world and 5,661st in the United States.
Employees
16
Change (1Y)
3
Growth (1Y)
23.08%
Revenue / Employee
n/a
Profits / Employee
-$1,892,188
Market Cap
602.43M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 16 | 3 | 23.08% |
| Mar 31, 2026 | 12 | -1 | -7.69% |
| Dec 31, 2025 | 13 | 0 | - |
| Sep 30, 2025 | 13 | 0 | - |
| Jun 30, 2025 | 13 | 0 | - |
| Mar 31, 2025 | 13 | 0 | - |
| Dec 31, 2024 | 13 | 0 | - |
| Sep 30, 2024 | 13 | 0 | - |
| Jun 30, 2024 | 13 | - | - |
| Dec 31, 2023 | 13 | 2 | 18.18% |
| Dec 31, 2022 | 11 | 3 | 37.50% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| Prime Medicine | 146 |
| Solid Biosciences | 121 |
| Aura Biosciences | 113 |
| Lexicon Pharmaceuticals | 81 |
| Design Therapeutics | 55 |
| Achieve Life Sciences | 28 |
| Immix Biopharma | 21 |
NVCT News
- 21 hours ago - Nuvectis Pharma’s NXP200 shows positive Phase 1b results in gliomas - TheFly
- 22 hours ago - Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas - GlobeNewsWire
- 12 days ago - Nuvectis Pharma Slides: Corporate presentation - Filings
- 17 days ago - Nuvectis Pharma to Participate in the Maxim Growth Summit 2026 - GlobeNewsWire
- 4 weeks ago - Nuvectis Pharma announces NXP200 granted BTD in China - TheFly
- 4 weeks ago - Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma - GlobeNewsWire
- 6 weeks ago - Nuvectis Pharma Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 6 weeks ago - Nuvectis Pharma Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts